Literature DB >> 18668620

Medical treatment of freezing of gait.

Nir Giladi1.   

Abstract

Freezing of gait (FOG) is frequently considered as one of the dopamine-resistant motor symptoms of Parkinsonism. Recent studies have clearly demonstrated that the Off-related FOG is improved by levodopa (L-dopa) or entacapone treatment. L-dopa can decrease duration of each FOG episode as well as its frequency. On-related FOGs are not common and difficult to diagnose. Only in the most advanced stages of the disease, FOGs are resistant to treatment as many other symptoms. Off-related FOGs are likely to be improved by dopamine agonists (DAs), but this has never been looked at systematically. In contrast, DA treatment might provoke FOG, and in two pivotal studies when DAs were compared to L-dopa in early stages of Parkinson's disease, the DA-treated arms experienced more FOGs. MAO-B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown. L-Threo-DOPS has been reported to have a symptomatic beneficial effect in patients with pure freezing syndrome, but small-scale, controlled trials in Parkinson's disease could not support those early observations. Botulinum toxin injected into the calf muscles has been suggested to have a symptomatic benefit. However, double-blind, prospective studies could not support that early observation and increased fall risk in the injected patients has put this direction of treatment on hold. The potential benefit of amantadine, antidepressive drugs, acetylcholine esterase inhibitors, and methylphenidate on FOG has been studied in small-scale studies, and there is a need for prospective studies to understand the future role of those drugs. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668620     DOI: 10.1002/mds.21914

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Managing Gait, Balance, and Posture in Parkinson's Disease.

Authors:  Bettina Debû; Clecio De Oliveira Godeiro; Jarbas Correa Lino; Elena Moro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-06       Impact factor: 5.081

3.  The Effect of Parkinson Drug Timing on Cardiovascular Response during Treadmill Exercise in a Person with Parkinson Disease and Freezing of Gait.

Authors:  Cheryl M Petersen; Reid Nelson; Teresa M Steffen
Journal:  Physiother Can       Date:  2013       Impact factor: 1.037

4.  Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease.

Authors:  Daniel Weiss; Sorin Breit; Tobias Wächter; Christian Plewnia; Alireza Gharabaghi; Rejko Krüger
Journal:  J Neurol       Date:  2011-02-02       Impact factor: 4.849

5.  Identifying the neural correlates of doorway freezing in Parkinson's disease.

Authors:  Elie Matar; James M Shine; Moran Gilat; Kaylena A Ehgoetz Martens; Philip B Ward; Michael J Frank; Ahmed A Moustafa; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2019-01-13       Impact factor: 5.038

6.  The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study.

Authors:  Moria Dagan; Talia Herman; Anat Mirelman; Nir Giladi; Jeffrey M Hausdorff
Journal:  Exp Brain Res       Date:  2017-05-16       Impact factor: 1.972

7.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

8.  Alterations of functional and structural connectivity of freezing of gait in Parkinson's disease.

Authors:  Min Wang; Siming Jiang; Yongsheng Yuan; Li Zhang; Jian Ding; Jianwei Wang; Jiejin Zhang; Kezhong Zhang; Jie Wang
Journal:  J Neurol       Date:  2016-05-26       Impact factor: 4.849

9.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

Review 10.  Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.

Authors:  Samuel D Kim; Natalie E Allen; Colleen G Canning; Victor S C Fung
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.